MS4A1 and B-cell chronic lymphocytic leukemia: For example, the CLL-14 trial comparing venetoclax with obinutuzumab (an anti-CD20 antibody) to chlorambucil with obintuzumab demonstrated a significantly longer 24-month PFS with the former regimen in patients with TP53 disrupted CLL [57].